Insights

Strategic Partnerships Orum Therapeutics announced a global, multi-target license and option agreement with Vertex, indicating a willingness to collaborate with industry leaders for product development. This presents an opportunity for strategic partnerships with other companies looking to leverage Orum's innovative technology.

Funding and Growth Receiving $15 million in financing and planning to go public on the Korea Exchange signals financial health and growth potential for Orum Therapeutics. This funding and IPO plans present an opportunity for investors seeking to support a biotech company on an upward trajectory.

Talent Acquisition With recent board and executive appointments, such as David Main as a Board of Directors and Olaf Christensen as Chief Medical Officer, Orum demonstrates a focus on acquiring top talent. This indicates room for collaboration with recruiting agencies or talent management firms that can help identify key personnel for the company's growth.

Product Development Orum's development of ORM-5029 as a targeted protein degrader therapy for HER2-expressing breast cancer showcases a commitment to innovative product development. Companies specializing in supporting drug development processes or clinical trials could find opportunities to collaborate with Orum in advancing this therapy to the market.

Competitive Landscape By selling assets to Bristol-Myers Squibb and being compared to peers like Neogene Therapeutics and Immunocore, Orum Therapeutics positions itself within a competitive landscape. Understanding the competitive dynamics in the biotech sector can provide sales teams with insights on differentiation strategies and potential areas for market penetration.

Orum Therapeutics Tech Stack

Orum Therapeutics uses 8 technology products and services including Google Analytics, Squarespace, Stimulus, and more. Explore Orum Therapeutics's tech stack below.

  • Google Analytics
    Analytics
  • Squarespace
    Content Management System
  • Stimulus
    Javascript Frameworks
  • Reddit
    Message Boards
  • Google
    Miscellaneous
  • HSTS
    Security
  • Twitter
    Widgets
  • Linkedin
    Widgets

Media & News

Orum Therapeutics's Email Address Formats

Orum Therapeutics uses at least 1 format(s):
Orum Therapeutics Email FormatsExamplePercentage
First.Last@orumrx.comJohn.Doe@orumrx.com
49%
LFirst@orumrx.comDJohn@orumrx.com
1%
First.Last@orumrx.comJohn.Doe@orumrx.com
49%
LFirst@orumrx.comDJohn@orumrx.com
1%

Frequently Asked Questions

Where is Orum Therapeutics's headquarters located?

Minus sign iconPlus sign icon
Orum Therapeutics's main headquarters is located at 1050 Waltham St Suite 101 Lexington, Massachusetts 02421 US. The company has employees across 2 continents, including North AmericaEurope.

What is Orum Therapeutics's official website and social media links?

Minus sign iconPlus sign icon
Orum Therapeutics's official website is orumrx.com and has social profiles on LinkedIn.

How much revenue does Orum Therapeutics generate?

Minus sign iconPlus sign icon
As of January 2025, Orum Therapeutics's annual revenue reached $3.8M.

What is Orum Therapeutics's SIC code NAICS code?

Minus sign iconPlus sign icon
Orum Therapeutics's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Orum Therapeutics have currently?

Minus sign iconPlus sign icon
As of January 2025, Orum Therapeutics has approximately 43 employees across 2 continents, including North AmericaEurope. Key team members include Chief Medical Officer: O. C.Chief Financial Officer: J. M.Vice President Global Human Resources: S. B.. Explore Orum Therapeutics's employee directory with LeadIQ.

What industry does Orum Therapeutics belong to?

Minus sign iconPlus sign icon
Orum Therapeutics operates in the Biotechnology Research industry.

What technology does Orum Therapeutics use?

Minus sign iconPlus sign icon
Orum Therapeutics's tech stack includes Google AnalyticsSquarespaceStimulusRedditGoogleHSTSTwitterLinkedin.

What is Orum Therapeutics's email format?

Minus sign iconPlus sign icon
Orum Therapeutics's email format typically follows the pattern of . Find more Orum Therapeutics email formats with LeadIQ.

How much funding has Orum Therapeutics raised to date?

Minus sign iconPlus sign icon
As of January 2025, Orum Therapeutics has raised $122M in funding. The last funding round occurred on Jun 23, 2021 for $84M.

When was Orum Therapeutics founded?

Minus sign iconPlus sign icon
Orum Therapeutics was founded in 2016.
Orum Therapeutics

Orum Therapeutics

Biotechnology ResearchMassachusetts, United States11-50 Employees

Orum Therapeutics is an oncology-focused, private, clinical stage biotech pioneering the development of antibody-enabled, dual-precision targeted protein homeostasis. We leverage our TPD² approach to provide targeted protein degraders, and TPS² approach to provide targeted protein stabilizers for cell-specific delivery to improve patient outcomes. Orum is located in Lexington, MA, USA and Daejeon, South Korea.

Section iconCompany Overview

Headquarters
1050 Waltham St Suite 101 Lexington, Massachusetts 02421 US
Website
orumrx.com
SIC Code
8733 - Noncommercial Research Organizations
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2016
Employees
11-50

Section iconFunding & Financials

  • $122M

    Orum Therapeutics has raised a total of $122M of funding over 3 rounds. Their latest funding round was raised on Jun 23, 2021 in the amount of $84Mas a Series B.

  • $10M

    Orum Therapeutics's revenue is in the range of $10M

Section iconFunding & Financials

  • $122M

    Orum Therapeutics has raised a total of $122M of funding over 3 rounds. Their latest funding round was raised on Jun 23, 2021 in the amount of $84Mas a Series B.

  • $10M

    Orum Therapeutics's revenue is in the range of $10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.